Compare ULBI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULBI | IPHA |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 119.1M |
| IPO Year | 1995 | N/A |
| Metric | ULBI | IPHA |
|---|---|---|
| Price | $6.52 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 69.4K | 17.5K |
| Earning Date | 03-10-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $191,159,000.00 | N/A |
| Revenue This Year | $20.00 | $181.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.24 | N/A |
| 52 Week Low | $4.07 | $1.18 |
| 52 Week High | $9.51 | $2.63 |
| Indicator | ULBI | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 38.04 |
| Support Level | $6.43 | $1.18 |
| Resistance Level | $7.24 | $1.88 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 48.34 | 29.41 |
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.